Cargando…

Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers

SIMPLE SUMMARY: Men with certain genetic differences are at much higher risks of developing metastatic and lethal prostate cancer. With the recent introduction of a new class of medications specifically targeted to these gene repair pathways (PARP inhibitors), it is critical to review the state of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clark, Roderick, Herrera-Caceres, Jaime, Kenk, Miran, Fleshner, Neil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870148/ https://www.ncbi.nlm.nih.gov/pubmed/35205755 http://dx.doi.org/10.3390/cancers14041004

Ejemplares similares

An appraisal of genetic testing for prostate cancer susceptibility
por: Finch, Amy, et al.
Publicado: (2022)

Population‐based analysis of perioperative chemotherapy use, interventions requiring hospitalization and atheroembolic events among patients with non‐metastatic muscle‐invasive bladder cancer
por: Benidir, Tarik, et al.
Publicado: (2021)

Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue
por: Nguyen, Linh T., et al.
Publicado: (2022)

Statin Use and Survival Among Men Receiving Androgen-Ablative Therapies for Advanced Prostate Cancer: A Systematic Review and Meta-analysis
por: Jayalath, Viranda H., et al.
Publicado: (2022)

A 38-gene model comprised of key TET2-associated genes shows additive utility to high-risk prostate cancer cases in the prognostication of biochemical recurrence
por: Kamdar, Shivani, et al.
Publicado: (2020)

The established risk of prostate cancer comorbidity in BRCA1/2 mutation carriers: where is the clinically relevant hotspot for prostate cancer?
por: Matsumoto, Takashi, et al.
Publicado: (2020)

Oral contraceptive use is associated with prostate cancer: an ecological study
por: Margel, David, et al.
Publicado: (2011)

Reproductive factors as risk modifiers of breast cancer in BRCA mutation carriers and high-risk non-carriers
por: Park, Boyoung, et al.
Publicado: (2017)

Salvage Radiotherapy Following Partial Gland Ablation for Prostate Cancer: Functional and Oncological Outcomes
por: Qaoud, Yazan, et al.
Publicado: (2020)

Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study
por: Toren, Paul, et al.
Publicado: (2013)

Management of the asymptomatic BRCA mutation carrier
por: Teller, Paige, et al.
Publicado: (2010)

Mesothelioma developing in carriers of inherited genetic mutations
por: Yoshikawa, Yoshie, et al.
Publicado: (2020)

Incorporating mpMRI biopsy data into established pre-RP nomograms: potential impact of an increasingly common clinical scenario
por: Leong, Joon Yau, et al.
Publicado: (2019)

Managing BRCA Mutation Carriers in China: Reply
por: Kwong, Ava, et al.
Publicado: (2010)

The Effects of Serum from Prostate Cancer Patients with Elevated Body Mass Index on Prostate Cancer Cells In Vitro
por: Mora, Benjamin C, et al.
Publicado: (2015)

Optimal Management of High-Risk T1G3 Bladder Cancer: A Decision Analysis
por: Kulkarni, Girish S, et al.
Publicado: (2007)

A narrative review of pelvic lymph node dissection in prostate cancer
por: Cheung, Douglas C., et al.
Publicado: (2020)

The potential impact of adding genetic markers to clinical parameters in managing high-risk prostate cancer patients
por: Alvarez-Cubero, Maria Jesus, et al.
Publicado: (2013)

Selected aspects of genetic counselling for BRCA1 mutation carriers
por: Gronwald, Jacek
Publicado: (2007)

Population-Based Estimate of Prostate Cancer Risk for Carriers of the HOXB13 Missense Mutation G84E
por: MacInnis, Robert J., et al.
Publicado: (2013)

Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis
por: Edwards, S M, et al.
Publicado: (2010)

Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores
por: Lecarpentier, Julie, et al.
Publicado: (2017)

Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management
por: Ramsoekh, Dewkoemar, et al.
Publicado: (2009)

Selenium and cancer risk in CHEK2 mutation carriers
por: Gupta, Satish, et al.
Publicado: (2012)

SAT-LB058 Effect of a Genetic Modifier of Cancer Risk in TP53 Mutation Carriers
por: Pinto, Emilia, et al.
Publicado: (2019)

Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial
por: Shore, Neal D., et al.
Publicado: (2022)

Management of Breast Cancer in BRCA1/2 Mutation Carriers
por: Eeles, R. A., et al.
Publicado: (1999)

Recommendations for the Management of Cardiomyopathy Mutation Carriers: Evidence, Doubts, and Intentions
por: Couto, José F., et al.
Publicado: (2023)

High genetic carrier frequency of Wilson’s disease in France: discrepancies with clinical prevalence
por: Collet, Corinne, et al.
Publicado: (2018)

Clinical and genetic characteristics of female dystrophinopathy carriers
por: Zhong, Jingzi, et al.
Publicado: (2019)

Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management
por: Doan, David K., et al.
Publicado: (2021)

DNA Damage Repair (DDR) Mutations and the Utility of High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC)
por: Rathi, Nityam, et al.
Publicado: (2018)

Clinical implications of the oncometabolite succinate in SDHx‐mutation carriers
por: Eijkelenkamp, Karin, et al.
Publicado: (2019)

Clinical Deep Phenotyping of ABCA7 Mutation Carriers
por: Campbell, Alana S., et al.
Publicado: (2022)

Comparison of Long-Term Oncological Results in Young Women with Breast Cancer between BRCA-Mutation Carriers Versus Non-Carriers: How Tumor and Genetic Risk Factors Influence the Clinical Prognosis
por: Tinterri, Corrado, et al.
Publicado: (2023)

Are Mutation Carrier Patients Different from Non-Carrier Patients? Genetic, Pathology, and US Features of Patients with Breast Cancer
por: Pintican, Roxana Maria, et al.
Publicado: (2022)

The Relationship Between Metformin and Serum Prostate‐Specific Antigen Levels
por: Jayalath, Viranda H., et al.
Publicado: (2016)

Selenium and genotypes as marker of risk in BRCA1 mutation carriers
por: Jaworska, K, et al.
Publicado: (2012)

Management of High-Risk Localized Prostate Cancer
por: Marciscano, Ariel E., et al.
Publicado: (2012)

Serum Adipokines as Predictors for the Outcome of Prostate Biopsies at Early Stage Prostate Cancer Diagnosis
por: Ahmad, Ardalan E, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lhlf5d8reqnhetifc753ikeqav